Correlation between Therapeutic Efficacy of CD34+ Cell Treatment and Directed In Vivo Angiogenesis in Patients with End-Stage Diffuse Coronary Artery Disease
Table 1
Clinical and laboratory findings of 30 study patients.
Variables
Low-score ()
High-score ()
value
Age (years)
65.3 ± 9.8
66.0 ± 6.3
0.799
Male gender
58.3% (7)
72.2% (13)
0.429
Body height (cm)
158.8 ± 8.1
161.9 ± 6.2
0.243
Body weight (kg)
67.4 ± 14.4
70.0 ± 10.2
0.200
Body mass index
26.1 ± 4.7
26.7 ± 3.7
0.692
Hypertension
91.7% (11)
83.3% (15)
0.632
Diabetes mellitus
75.0% (9)
83.3% (15)
0.660
History or current smoking
33.3% (4)
50.0% (9)
0.367
Total cholesterol (mg/dL)
182.1 ± 36.3
164.4 ± 42.1
0.246
Low density lipoprotein
102.9 ± 25.5
106.0 ± 40.1
0.815
High density lipoprotein
47.6 ± 13.1
42.8 ± 8.5
0.238
Previous stroke
16.7% (2)
22.2% (4)
1.000
Old myocardial infarction
16.7% (2)
16.7% (3)
1.000
History of CABG
41.7% (5)
33.3% (6)
0.643
Diffuse multivessel disease
100% (12)
100% (18)
1.000
Diffuse triple vessel disease
83.3% (10)
83.3% (15)
1.000
Previous PCI
58.3% (7)
44.4% (8)
0.456
Aspirin/clopidogrel therapy
100% (12)
100% (18)
1.000
β-Blocker therapy
91.7% (11)
94.4% (17)
1.000
Stain therapy
58.3% (7)
77.8% (14)
0.255
ARB/ACEI therapy
75.0% (9)
77.8% (14)
1.000
Creatinine level (mg/dL)
1.08 ± 0.31
1.26 ± 0.42
0.391
Creatinine clearance rate (mL/min)
64.8 ± 17.7
59.9 ± 23.1
0.539
Stage III–IV CKD
58.3% (7)
55.6% (10)
0.880
Flow cytometry (before G-CSF treatment)
KDR+/CD34+/CD45− (%)
0.22 ± 0.19
0.24 ± 0.14
0.430
CD133+/CD34+/CD45− (%)
0.12 ± 0.11
0.08 ± 0.05
0.458
CD34+ (%)
1.19 ± 0.91
1.05 ± 1.02
0.711
Flow cytometry (after G-CSF treatment)
KDR+/CD34+/CD45− (%)
0.52 ± 0.67
0.34 ± 0.55
0.325
CD133+/CD34+/CD45− (%)
1.10 ± 0.87
0.75 ± 0.52
0.347
CD34+ (%)
2.42 ± 2.08
1.88 ± 1.65
0.879
Data are expressed as or % (n). CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; ARB = angiotensin II type I receptor blocker, ACEI = angiotensin-converting enzyme inhibitor; CKD = chronic kidney disease.
